Cargando…

Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales

Type 2 diabetes mellitus (T2DM) continues to be a substantial medical problem due to its increasing global prevalence and because chronic hyperglycemic states are closely linked with obesity, liver disease and several cardiovascular diseases. Since the early discovery of insulin, numerous antihyperg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dahlén, Amelia D., Dashi, Giovanna, Maslov, Ivan, Attwood, Misty M., Jonsson, Jörgen, Trukhan, Vladimir, Schiöth, Helgi B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807560/ https://www.ncbi.nlm.nih.gov/pubmed/35126141 http://dx.doi.org/10.3389/fphar.2021.807548

Ejemplares similares

Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
por: Tay-Teo, Kiu, et al.
Publicado: (2019)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs
por: Van Norman, Gail A.
Publicado: (2016)

Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library
por: Pascoalino, Bruno S., et al.
Publicado: (2016)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines
por: Namiot, Eugenia D., et al.
Publicado: (2023)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

Water Networks in Complexes between Proteins and FDA-Approved Drugs
por: Samways, Marley L., et al.
Publicado: (2022)

Ebanga™: The most recent FDA-approved drug for treating Ebola
por: Taki, Elahe, et al.
Publicado: (2023)

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
por: Rizzo, Carla, et al.
Publicado: (2023)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
por: Shabir, Ghulam, et al.
Publicado: (2023)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Synthesis and clinical application of new drugs approved by FDA in 2022
por: Zhang, Jing-Yi, et al.
Publicado: (2023)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
por: Nunes, Débora, et al.
Publicado: (2022)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Classification of Trispanins: A Diverse Group of Proteins That Function in Membrane Synthesis and Transport Mechanisms
por: Attwood, Misty M., et al.
Publicado: (2020)

Characterization of Five Transmembrane Proteins: With Focus on the Tweety, Sideroflexin, and YIP1 Domain Families
por: Attwood, Misty M., et al.
Publicado: (2021)

Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)
por: Maslov, Ivan O., et al.
Publicado: (2022)

Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi
por: Planer, Joseph D., et al.
Publicado: (2014)

Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
por: Wu, Leihong, et al.
Publicado: (2019)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection
por: Wang, Shaobo, et al.
Publicado: (2017)

Exploring anti-malarial potential of FDA approved drugs: an in silico approach
por: Ramakrishnan, Gayatri, et al.
Publicado: (2017)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kbm6gnfv1pd8jp9f6609e6ht74